首页> 美国卫生研究院文献>Pharmaceutics >Erythrocyte Membrane Cloaked Curcumin-Loaded Nanoparticles for Enhanced Chemotherapy
【2h】

Erythrocyte Membrane Cloaked Curcumin-Loaded Nanoparticles for Enhanced Chemotherapy

机译:红细胞膜隐蔽姜黄素负载的纳米颗粒增强化学疗法。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, curcumin-loaded porous poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were prepared and surface modified with red blood cell membranes (RBCM) to yield biomimetic RBCM-p-PLGA@Cur NPs. The NPs displayed a visible cell-membrane structure at their exterior and had a uniform size of 162 ± 3 nm. In vitro studies showed that drug release from non-porous PLGA NPs was slow and that much of the drug remained trapped in the NPs. In contrast, release was accelerated from the porous PLGA NPs, and after the RBCM coating, a sustained release over 48 h was obtained. Confocal microscopy and flow cytometry results revealed that the RBCM-p-PLGA NPs led to a greater cellular uptake by H22 hepatocarcinoma cells than the uncoated analogue NPs, but could avoid phagocytosis by macrophages. The drug-free formulations were highly biocompatible, while the drug-loaded systems were effective in killing cancer cells. RBCM-p-PLGA@Cur NPs possess potent anti-tumor activity in a murine H22 xenograft cancer model (in terms of reduced tumor volume and mass, as well as inducing apoptosis of tumor cells), and have no observable systemic toxicity. Overall, our study demonstrates that the use of the RBCM to cloak nanoscale drug delivery systems holds great promise for targeted cancer treatment, and can ameliorate the severe side effects currently associated with chemotherapy.
机译:在这项研究中,制备了姜黄素负载的多孔聚乳酸-乙醇酸共聚物(PLGA)纳米颗粒(NPs),并用红细胞膜(RBCM)对其进行了表面修饰,从而产生了仿生的RBCM-p-PLGA @ Cur NPs。 NP在其外部显示出可见的细胞膜结构,并具有162±3 nm的均匀大小。体外研究表明,从无孔PLGA NP释放药物的速度很慢,并且大部分药物仍被困在NP中。相比之下,从多孔PLGA NPs释放加快,并且在RBCM包衣后,在48小时内获得了持续释放。共聚焦显微镜和流式细胞仪结果表明,RBCM-p-PLGA NPs导致H22肝癌细胞的细胞摄取比未包被的类似物NPs大,但可以避免巨噬细胞的吞噬作用。无药物制剂具有高度的生物相容性,而载药系统可有效杀死癌细胞。 RBCM-p-PLGA @ Cur NP在鼠H22异种移植癌模型中具有有效的抗肿瘤活性(就减小的肿瘤体积和质量以及诱导肿瘤细胞的凋亡而言),并且没有可观察到的全身毒性。总体而言,我们的研究表明,使用RBCM掩盖纳米级药物输送系统具有针对性靶向癌症治疗的巨大希望,并且可以缓解目前与化学疗法相关的严重副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号